Literature DB >> 7777346

Fundamental immune mechanisms of the brain and inner ear.

J P Harris1, A F Ryan.   

Abstract

Because of the blood-brain and blood-labyrinthine barriers, the brain and inner ear were once thought to be immunoprivileged sites. Although these barriers provide protection from inflammatory damage to the delicate structures of the organs, both sites have since been shown to be capable of active immune responses when appropriately stimulated. In the inner ear, perisacular tissue around the endolymphatic sac hosts resident lymphocytes and serves as a site of immunosurveillance. Lymphocytes also enter the inner ear from the circulation, and in the cochlea this occurs via the spiral modiolar vein. Immune responses can protect the labyrinth from infection, but they can also cause bystander injury. Moreover, the cochlea can itself become the target of immune responses that damage hearing. Such autoimmune sensorineural hearing loss can be site specific, with the primary manifestation of the disorder being hearing loss and dysequilibrium. Some of these cases can be diagnosed by antibody or lymphocyte responses to inner ear antigens. Alternately, systemic autoimmune disorders can result in inner ear dysfunction as part of a broader spectrum of disease. Both forms of immune-mediated inner ear dysfunction may respond to immunosuppressive therapies, including steroids, cytotoxic agents, and plasmapheresis.

Entities:  

Mesh:

Year:  1995        PMID: 7777346     DOI: 10.1016/s0194-5998(95)70170-2

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  21 in total

1.  ERK2-dependent activation of c-Jun is required for nontypeable Haemophilus influenzae-induced CXCL2 upregulation in inner ear fibrocytes.

Authors:  Sejo Oh; Jeong-Im Woo; David J Lim; Sung K Moon
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

2.  Systemic immunity influences hearing preservation in cochlear implantation.

Authors:  Melanie Souter; Hayden Eastwood; Paul Marovic; Gordana Kel; Sarin Wongprasartsuk; Allen F Ryan; Stephen John O'Leary
Journal:  Otol Neurotol       Date:  2012-06       Impact factor: 2.311

Review 3.  Emerging Gene Therapies for Genetic Hearing Loss.

Authors:  Hena Ahmed; Olga Shubina-Oleinik; Jeffrey R Holt
Journal:  J Assoc Res Otolaryngol       Date:  2017-08-16

Review 4.  Sound strategies for hearing restoration.

Authors:  Gwenaëlle S G Géléoc; Jeffrey R Holt
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

Review 5.  Allergy and Ménière's disease.

Authors:  M Jennifer Derebery; Karen I Berliner
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

6.  Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss.

Authors:  Dennis R Trune; J Beth Kempton
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

Review 7.  Prospects for replacement of auditory neurons by stem cells.

Authors:  Fuxin Shi; Albert S B Edge
Journal:  Hear Res       Date:  2013-01-28       Impact factor: 3.208

8.  An engineered three-dimensional stem cell niche in the inner ear by applying a nanofibrillar cellulose hydrogel with a sustained-release neurotrophic factor delivery system.

Authors:  Hsiang-Tsun Chang; Rachel A Heuer; Andrew M Oleksijew; Kyle S Coots; Christian B Roque; Kevin T Nella; Tammy L McGuire; Akihiro J Matsuoka
Journal:  Acta Biomater       Date:  2020-03-07       Impact factor: 8.947

9.  Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease.

Authors:  Qing Cai; Xiaoping Du; Bin Zhou; Chun Cai; Mohammad Habiby Kermany; Taijune Yoo
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2009-04-10       Impact factor: 1.538

10.  Toxicology study for magnetic injection of prednisolone into the rat cochlea.

Authors:  M Shimoji; B Ramaswamy; M I Shukoor; P Benhal; A Broda; S Kulkarni; P Malik; B McCaffrey; J-F Lafond; A Nacev; I N Weinberg; B Shapiro; D A Depireux
Journal:  Eur J Pharm Sci       Date:  2018-06-19       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.